NEW YORK, Aug. 22, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Envision Healthcare Corporation (NYSE:EVHC) from March 2, 2015 through July 21, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Envision investors under the federal securities laws.
To join the Envision class action, go to http://rosenlegal.com/cases-1168.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Envision’s operating subsidiary, EmCare Holdings, Inc., routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (3) Envision’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (4) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result, Envision’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1168.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
OpenAI Addresses Security Vulnerability in macOS App Certification Process
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



